Novo Nordisk's Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM (DKK 255.55, 0.00)
StreetAccount Sector Summary - Healthcare Pre-Market
Dr. Reddy's Laboratories confirms receipt of marketing authorization for generic semaglutide injection in Canada (INR 1354.75, 0.00)
Health Canada approves first generic of Ozempic - Bloomberg (INR 1354.75, 0.00)
Novo Nordisk to present new data on Wegovy at European Congress on Obesity (DKK 263.50, 0.00)
European macro headlines:
Prothena partner Novo Nordisk obtains fast track designation from the U.S. FDA for Coramitug in ATTR-CM
StreetAccount Sector Summary - Healthcare Weekly Recap
Street Takeaways - GLP-1 Rx Tracker for week ended April 17th; Foundayo Week 2 TRx 3.71K vs 1.39K w/w; Oral Wegovy TRx rises ~9.9% w/w ($880.03, -37.62)
Powered by FactSet Research Systems Inc.